Puma Biotechnology (PBYI) Goodwill & Intangibles (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly Goodwill & Intangibles came in at $39.0 million in Q1 2026, down 20.0% YoY from $48.7 million in Q1 2025, and down 5.88% on a QoQ basis from $41.4 million in Q4 2025.
Analysis
Puma Biotechnology (PBYI) Goodwill & Intangibles (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Goodwill & Intangibles data on file, last reported at $39.0 million in Q1 2026.
- Quarterly Goodwill & Intangibles fell 20.0% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.0 million (down 20.0% YoY) and the FY2025 annual result came in at $41.4 million, down 19.05% from the prior year.
- Goodwill & Intangibles slipped to $39.0 million in Q1 2026, from $41.4 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $70.6 million in Q4 2022 to a low of $39.0 million in Q1 2026.
- A 5-year average of $56.1 million and a median of $58.4 million in 2024 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles increased 6.78% — and 2026, when it fell 20.0%.
- Tracing PBYI's Goodwill & Intangibles over 5 years: stood at $70.6 million in 2022, then retreated by 13.79% to $60.9 million in 2023, then fell by 16.0% to $51.1 million in 2024, then dropped by 19.05% to $41.4 million in 2025, then decreased by 5.88% to $39.0 million in 2026.
- The last three Goodwill & Intangibles figures came in at $39.0 million (Q1 2026), $41.4 million (Q4 2025), and $43.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.52 Mn |
| Mar 31, 2026 | 38.96 Mn |
| Dec 31, 2025 | 41.39 Mn |
| Sep 30, 2025 | 43.83 Mn |
| Jun 30, 2025 | 46.26 Mn |
| Mar 31, 2025 | 48.70 Mn |
| Dec 31, 2024 | 51.13 Mn |
| Sep 30, 2024 | 53.57 Mn |
| Jun 30, 2024 | 56.00 Mn |
| Mar 31, 2024 | 58.44 Mn |
| Dec 31, 2023 | 60.87 Mn |
| Sep 30, 2023 | 63.31 Mn |
| Jun 30, 2023 | 65.74 Mn |
| Mar 31, 2023 | 68.18 Mn |
| Dec 31, 2022 | 70.61 Mn |
| Sep 30, 2022 | 60.11 Mn |
| Jun 30, 2022 | 62.12 Mn |
| Mar 31, 2022 | 64.12 Mn |
| Dec 31, 2021 | 66.13 Mn |
| Sep 30, 2021 | 68.13 Mn |